Cargando…

Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer

BACKGROUND: The breast cancer microenvironment contributes to tumor progression and response to chemotherapy. Previously, we reported that increased stromal Type X collagen α1 (ColXα1) and low TILs correlated with poor pathologic response to neoadjuvant therapy in estrogen receptor and HER2-positive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Chaohui Lisa, Singh, Kamaljeet, Brodsky, Alexander S., Lu, Shaolei, Graves, Theresa A., Fenton, Mary Anne, Yang, Dongfang, Sturtevant, Ashlee, Resnick, Murray B., Wang, Yihong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825361/ https://www.ncbi.nlm.nih.gov/pubmed/31675929 http://dx.doi.org/10.1186/s12885-019-6134-y

Ejemplares similares

Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer
por: Brodsky, Alexander S., et al.
Publicado: (2016)

ColXα1 is a stromal component that colocalizes with elastin in the breast tumor extracellular matrix
por: Wang, Yihong, et al.
Publicado: (2018)

The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer
por: Eustace, A. J., et al.
Publicado: (2021)

HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?
por: Batra, Atul, et al.
Publicado: (2020)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Intratumoral heterogeneity, treatment response, and survival outcome of ER‐positive HER2‐positive breast cancer
por: Teruya, Natsuki, et al.
Publicado: (2023)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer
por: Basho, Reva K., et al.
Publicado: (2018)

Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term
por: Jankowitz, Rachel C, et al.
Publicado: (2012)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer()
por: Harbeck, Nadia
Publicado: (2022)

Reply to Letter to Editor: “HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?”
por: Li, Shuai, et al.
Publicado: (2020)

High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
por: Voutsadakis, Ioannis A.
Publicado: (2022)

Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
por: Hu, Taobo, et al.
Publicado: (2021)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
por: Lluch-Gómez, J., et al.
Publicado: (2023)

Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor
por: Andreani, Cristina, et al.
Publicado: (2017)

Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation
por: Lakis, Nelli S., et al.
Publicado: (2022)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019)

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
por: Buus, Richard, et al.
Publicado: (2018)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
por: Qing, Tao, et al.
Publicado: (2022)

Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date
por: Varella, Leticia, et al.
Publicado: (2023)

High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2−Negative Postmenopausal Breast Cancer Patients
por: Pousette, Jenny, et al.
Publicado: (2022)

Claudin Expression in High Grade Invasive Ductal Carcinoma of the Breast: Correlation with the Molecular Subtype
por: Lu, Shaolei, et al.
Publicado: (2012)

Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2− node positive breast cancer—A National Cancer Database study
por: Peethambaram, Prema P., et al.
Publicado: (2017)

Fatty acid binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon γ pathway
por: Wood, Stephanie M, et al.
Publicado: (2016)

Alterations in mRNA profiles of trastuzumab-resistant Her-2-positive breast cancer
por: Zhao, Bin, et al.
Publicado: (2018)

Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023)

Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
por: Cao, Lu, et al.
Publicado: (2016)

Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
por: Sardesai, Sagar, et al.
Publicado: (2020)

Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis
por: Peleg Hasson, S., et al.
Publicado: (2021)

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
por: Prat, A., et al.
Publicado: (2012)

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
por: Rigter, L S, et al.
Publicado: (2013)

Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer
por: Kim, Yun Yeong, et al.
Publicado: (2018)

Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7
por: Suga, Junko, et al.
Publicado: (2018)

Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells
por: Baumann, Jan, et al.
Publicado: (2016)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ryu, Ho Hyun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5ds2p087sp5sh9f6drseekuj9f